Last reviewed · How we verify

Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy

61 treatments

Approved treatments

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

Frequently asked questions about Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy

What drugs treat Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy?

Tracked treatments include Avelumab (MSB0010718C).

What is the treatment for Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy?

Standard treatment for Pembrolizumab plus chemotherapy for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy includes Avelumab (MSB0010718C). See the treatment landscape page for first-line, second-line and salvage options.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing